<DOC>
	<DOCNO>NCT00206947</DOCNO>
	<brief_summary>The present study specify delineate separate component cognitive deficit examine effect adjunctive cholinergic augmentation cognitive deficit well psychopathology schizophrenic patient treat antipsychotic compound aberrant bind affinity cholinergic receptor system . The hypothesis cholinergic augmentation use donepezil improve cognitive deficit , sensory gate deficit , psychopathology schizophrenic patient treat atypical antipsychotic ( ziprasidone ) .</brief_summary>
	<brief_title>The CAMPUS Project : Cholinergic Augmentation Cognitive Deficits Schizophrenia</brief_title>
	<detailed_description>The purpose study examine effect cholinergic augmentation atypical antipsychotic medication : - Cognitive deficit - Sensorimotor gate - Psychopathology The primary objective examine : â€¢ The effect donepezil , compare effect placebo , cognitive function , sensorimotor gate psychopathology patient treat atypical antipsychotic ( ziprasidone ) . Secondary objective examine : - The effect donepezil , compare effect placebo , cognitive function , sensorimotor gate psychopathology patient treat ziprasidone . - Which specific area cognitive deficit benefit cholinergic augmentation atypical antipsychotic treatment . - The interaction cognitive deficit psychopathology : To extent effect cholinergic augmentation psychopathology , sensorimotor gating , cognition independent correlate . - Which specific brain area activate cholinergic augmentation treatment atypical antipsychotic drug ( ziprasidone ) . Participants : Schizophrenic men woman age 18 55 meet ICD-10 criterion schizophrenia live catchment area psychiatric department Bispebjerg University Hospital , Rigshospitalet , Psychiatric Center , Glostrup . Patients either unmedicated , need switch antipsychotic medication due side-effects , lack effect negative symptom , positive symptom , cognitive function . Patients enrol study inpatient outpatient , change hospitalization status trial allow . Patients stabilize antipsychotic medication ( ziprasidone ) randomize treatment either donepezil placebo .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<criteria>Patients : Men woman age 18 55 meet ICD10 criterion schizophrenia live catchment area psychiatric department Bispebjerg University Hospital , Psychiatric Center , Glostrup Rigshospitalet . Patients either unmedicated , need switch antipsychotic medication due sideeffects , lack effect negative symptom , positive symptom , cognitive function . Controls : Healthy men woman match accord gender , age , socioeconomic status ( determine level education income parent ) . Patients : Patients hospitalize . Patients serious medical illness laboratory abnormality , pharmacotherapy pose substantial clinical risk ; pregnant lactating patient ; patient organic psychosis , history severe head trauma convulsive disorder , patient mental retardation . Patients significant alcohol drug dependence exclude . Controls : Pregnant lactate woman ; history severe head trauma ; mental retardation ; learn difficulty ; history psychiatric illness familial predisposition psychiatric illness ( firstdegree relative ) ; significant alcohol drug dependence ; episodic incident excessive alcohol consumption drug abuse reason exclusion . Abuse monitor interview patient measure urine content amphetamine , cannabinoles , opiate , benzodiazepine . Concomitant use benzodiazepine agitation insomnia ( oxazepam 45 mg daily ) allow need use conservatively trial . Use anticholinergic compound allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Cognitive deficit</keyword>
	<keyword>Cholinergic Augmentation</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>